GSK-1070806 is under clinical development by GSK and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GSK-1070806’s likelihood of approval (LoA) and phase transition for Atopic Dermatitis (Atopic Eczema) took place on 26 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GSK-1070806 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GSK-1070806 is under development for the treatment of Crohn's disease and moderate to severe atopic dermatitis (AtD). The drug candidate is administered intravenously as a solution. GSK-1070806 is a humanized IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). It was also under development for the treatment of type 2 diabetes and delayed graft function after renal transplantation. It was also under development for Behcet's disease.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
Quick View GSK-1070806 LOA Data
|Highest Development Stage|